About us

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers.

Pure Biologics also offers commercial partnership options  in several areas including early phase biological drug discovery and development, selection and characterization of antibodies and aptamers, as well as protein production, purification and analysis.

Harnessing the power of antibodies and aptamers
Play movie

Pure Biologics has been operating on the market since 2010. Its headquarters and laboratories are located in Wrocław, Poland. Main areas of activity include biotechnology, biological drug discovery and modern therapeutic solutions based on antibodies and aptamers. Employing app. 50 people, and with a broad portfolio, Pure Biologics is one of Poland’s largest biotechnology companies.

Due to its highly experienced research staff, cutting-edge infrastructure and business acumen, the Company conducts all phases of drug development – from target selection and validation to preclinical studies – on its own.

Additionally, by specializing in the selection of aptamers and antibodies, and in the biophysical analysis of molecular interactions, and the production and analysis of recombinant proteins, Pure Biologics is engaging into partnership with pharmaceutical and biotechnological companies, as well as research institutes all over the world.

In 2022 Pure Biologics has established a special purpose vehicle Doto Medical – focused on the accelerated development and commercialization of the key aptamer project in its portfolio – PB103, implemented in cooperation with the established on the biomedical market Dutch company Relitech BV. The project aims to develop a medical device for patients with Chronic Kidney Disease (CKD). At the same time, the company established cooperation with a renowned transaction advisor, Clairfield Partners.

R&D projects
R&D projects
Molecules screened
Molecules screened

Pure Biologics’ therapeutic portfolio includes new immunooncology therapies and non-systemic treatment of autoimmune, neurodegenerative and rare diseases. It is a total of a dozen projects, including five key projects in which we use antibody and aptamer technologies to develop molecules with therapeutic potential.

Pure Biologics comprises a team of extremely talented and energetic people who pursue their goals with passion. Our team consists of employees with broad competences and extensive experience gained in research units from around the world.


Pure Biologics incorporation
first business partners in the area of recombinant proteins
headquarters and laboratories moved to Wroclaw Technology Park
start of internal R&D activities
first R&D projects with Polish and foreign grants
transformation into Limited Liability Corporation
first patent application in the field of aptamers
start of internal research on the development of biologically active molecules – antibody and aptamer selection
PB001 and PB002 projects receive funding
Pure Biologics becomes a member of the Horizon2020 project consortium
transformation into a joint-stock company and entering the NewConnect market of the Warsaw Stock Exchange
PB003, PB004, PB005 and PB006 projects receive funding
aptamer patent granted for the USA
entering the Main Market of the Warsaw Stock Exchange
aptamer patent granted for the EU
Establishment of a special purpose vehicle focused on accelerated development of the aptamer project PB103
Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers